

BEST AVAILABLE COPY

RECEIVED
CENTRAL FAX CENTER

Docket No.: 213.1152-CIP

OCT 02 2006

UNITED STATES PATENT & TRADEMARK OFFICE

Examiner: VIVLEMORE, Tracy Ann Art Unit: 1635

Applicant: ZHAO, Hong, et al.

Serial No.: 10/822,205

Filed: April 9, 2004

For: POLYMERIC OLIGONUCLEOTIDE
PRODRUGS

Confirmation No.: 3686

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTVIA FACSIMILE 571-273-8300

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

October 2, 2006

Sir:

Further to the Information Disclosure Statement submitted on May 31, 2005, and pursuant to M.P.E.P. §609 and 37 C.F.R. §§1.56, 1.97-1.99, Applicants herewith submit form PTO-1449 (1 page), which lists references cited in the International Search Report (ISR) dated September 14, 2006. A copy of the ISR and Written Opinion of the International Search Authority is enclosed herewith. Applicants have not included references already made of record in the application on form PTO-1449. Additionally, it is noted that Applicants have not enclosed copies of the U.S. patent and U.S. patent application publication cited on form PTO-1449.

This submission does not represent that a search has been made or that no better art exists. While the term "references" is used in citing the documents called to the Examiner's attention herein, Applicants do not make any admission that each or all of them are "prior art" references within the meaning of the statutory and case law.

Applicants reserve the right to contend, where appropriate, that a reference asserted against any claim of the present application is not prior art under the facts and the law.


Applicants also reserve the right to present appropriate arguments and/or evidence to establish patentability over the references, should one or more of the references be applied against the claims of the present application.

Applicants request that the Examiner independently determine those items which the Examiner would consider the most pertinent of all the references cited herein.

This Information Disclosure Statement is filed before the mailing date of any of a final action under §1.113, a notice of allowance §1.311, or an action that closes prosecution in the application. Each item of information contained in the IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS. Accordingly, this document complies with the requirements of 37 C.F.R. §1.97 (c) and (e). It is respectfully requested that the references cited in the accompanying PTO-1449 form be considered and made of record.

No fee is believed to be due. Any deficiency or overpayment concerning this document should be charged or credited to Deposit Account No. 02-2275.

Respectfully submitted,


LUCAS & MERCANTI, LLP
Michael N. Mercanti
Registration No. 33,966

LUCAS & MERCANTI, LLP
475 Park Avenue South
New York, NY 10016
Phone: 212-661-8000
Fax: 212-661-8002

CERTIFICATE OF FACSIMILE TRANSMISSION
I hereby certify that this document is being facsimile transmitted to the Commissioner of Patents on the date shown below.

October 2, 2006

LUCAS & MERCANTI, LLP

BY:


Michael N. Mercanti

